Stefan Kaufmann
Director/Board Member at Bio Ventures for Global Health
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Donald Joseph | M | 70 |
Bio Ventures for Global Health
| 14 years |
| James C. Greenwood | M | - |
Bio Ventures for Global Health
| - |
| Nadine Weich | M | - |
Bio Ventures for Global Health
| 14 years |
| Robert Chess | M | 66 |
Bio Ventures for Global Health
| - |
| Jennifer Dent | F | - |
Bio Ventures for Global Health
| - |
| Bernd Eisele | M | - |
Vakzine Projekt Management GmbH
 Vakzine Projekt Management GmbH Pharmaceuticals: MajorHealth Technology Vakzine Projekt Management GmbH develops vaccines and biopharmaceuticals products from laboratory stages through to clinical examination. It offers VPM2001 vaccine to prevent human cytomegalovirus infections and VPM5001 Soluferon vaccine, treatment for multiple sclerosis (MS) and hepatitis C. The company was founded in August 2002 and is headquartered in Hannover, Germany. | 21 years |
| Carl Feldbaum | M | 80 |
Bio Ventures for Global Health
| 20 years |
| Michael Manns | M | 73 |
Vakzine Projekt Management GmbH
Vakzine Projekt Management GmbH Pharmaceuticals: MajorHealth Technology Vakzine Projekt Management GmbH develops vaccines and biopharmaceuticals products from laboratory stages through to clinical examination. It offers VPM2001 vaccine to prevent human cytomegalovirus infections and VPM5001 Soluferon vaccine, treatment for multiple sclerosis (MS) and hepatitis C. The company was founded in August 2002 and is headquartered in Hannover, Germany. | - |
| Inge Jacobi | F | 61 |
Vakzine Projekt Management GmbH
Vakzine Projekt Management GmbH Pharmaceuticals: MajorHealth Technology Vakzine Projekt Management GmbH develops vaccines and biopharmaceuticals products from laboratory stages through to clinical examination. It offers VPM2001 vaccine to prevent human cytomegalovirus infections and VPM5001 Soluferon vaccine, treatment for multiple sclerosis (MS) and hepatitis C. The company was founded in August 2002 and is headquartered in Hannover, Germany. | 21 years |
| Molly Polen | F | - |
Bio Ventures for Global Health
| - |
| Jacqueline Papkoff | M | - |
Bio Ventures for Global Health
| 14 years |
| Michael Bröker | M | - |
Vakzine Projekt Management GmbH
Vakzine Projekt Management GmbH Pharmaceuticals: MajorHealth Technology Vakzine Projekt Management GmbH develops vaccines and biopharmaceuticals products from laboratory stages through to clinical examination. It offers VPM2001 vaccine to prevent human cytomegalovirus infections and VPM5001 Soluferon vaccine, treatment for multiple sclerosis (MS) and hepatitis C. The company was founded in August 2002 and is headquartered in Hannover, Germany. | - |
| Leander Grode | M | 54 |
Vakzine Projekt Management GmbH
Vakzine Projekt Management GmbH Pharmaceuticals: MajorHealth Technology Vakzine Projekt Management GmbH develops vaccines and biopharmaceuticals products from laboratory stages through to clinical examination. It offers VPM2001 vaccine to prevent human cytomegalovirus infections and VPM5001 Soluferon vaccine, treatment for multiple sclerosis (MS) and hepatitis C. The company was founded in August 2002 and is headquartered in Hannover, Germany. | - |
| Rolf Guenter Werner | M | - |
Vakzine Projekt Management GmbH
Vakzine Projekt Management GmbH Pharmaceuticals: MajorHealth Technology Vakzine Projekt Management GmbH develops vaccines and biopharmaceuticals products from laboratory stages through to clinical examination. It offers VPM2001 vaccine to prevent human cytomegalovirus infections and VPM5001 Soluferon vaccine, treatment for multiple sclerosis (MS) and hepatitis C. The company was founded in August 2002 and is headquartered in Hannover, Germany. | - |
| Peter Lange | M | 80 |
Vakzine Projekt Management GmbH
Vakzine Projekt Management GmbH Pharmaceuticals: MajorHealth Technology Vakzine Projekt Management GmbH develops vaccines and biopharmaceuticals products from laboratory stages through to clinical examination. It offers VPM2001 vaccine to prevent human cytomegalovirus infections and VPM5001 Soluferon vaccine, treatment for multiple sclerosis (MS) and hepatitis C. The company was founded in August 2002 and is headquartered in Hannover, Germany. | - |
| Matt Rieke | M | - |
Bio Ventures for Global Health
| - |
| Peter Buckel | M | 79 |
Vakzine Projekt Management GmbH
Vakzine Projekt Management GmbH Pharmaceuticals: MajorHealth Technology Vakzine Projekt Management GmbH develops vaccines and biopharmaceuticals products from laboratory stages through to clinical examination. It offers VPM2001 vaccine to prevent human cytomegalovirus infections and VPM5001 Soluferon vaccine, treatment for multiple sclerosis (MS) and hepatitis C. The company was founded in August 2002 and is headquartered in Hannover, Germany. | - |
| James Geraghty | M | 69 |
Bio Ventures for Global Health
| 14 years |
| G. Steven Burrill | M | 79 |
Bio Ventures for Global Health
| 14 years |
| Vaughn M. Kailian | M | 79 |
Bio Ventures for Global Health
| - |
| J. Read | M | 73 |
Bio Ventures for Global Health
| - |
| Katy Graef | F | - |
Bio Ventures for Global Health
| - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Frank Stubhan | M | 59 |
Universität Ulm
| 8 years |
| Mike Kunze | M | - |
Universität Ulm
| 11 years |
| Roland Folz | M | 60 |
Universität Ulm
| 5 years |
| Wolfgang Heinz Büchele | M | 64 |
Universität Ulm
| 8 years |
| Helmut Wagner | M | 73 |
The Johannes Gutenberg University of Mainz
| 5 years |
| Ulrich Heinle | M | - |
Universität Ulm
| 4 years |
| Markus Weber | M | 51 |
Universität Ulm
| 4 years |
| Thomas Richter | M | - |
Universität Ulm
| 5 years |
| Franz Josef Jung | M | 75 |
The Johannes Gutenberg University of Mainz
| 3 years |
| Peter Werner | M | 72 |
The Johannes Gutenberg University of Mainz
| 1 years |
| Axel Müller | M | 67 |
The Johannes Gutenberg University of Mainz
| 10 years |
| Alexandra Dürr | M | 62 |
Universität Ulm
| 3 years |
| Hans-Hermann Lotter | M | 60 |
Universität Ulm
| 4 years |
| Heinz Otto Geidt | M | 70 |
The Johannes Gutenberg University of Mainz
| 4 years |
| Heinz-Peter Labonte | M | 74 |
The Johannes Gutenberg University of Mainz
| 4 years |
| Ertugrul Sönmez | M | - |
Universität Ulm
| 4 years |
| Renate Köcher | M | 71 |
The Johannes Gutenberg University of Mainz
| 4 years |
| Ingo Daumiller | M | - |
Universität Ulm
| 4 years |
| John Lyons | M | - |
Universität Ulm
| 3 years |
| Günther Bräunig | M | 68 |
The Johannes Gutenberg University of Mainz
| 3 years |
| Lothar Steinebach | M | 76 |
The Johannes Gutenberg University of Mainz
| 5 years |
| Claus-Michael Dill | M | 70 |
The Johannes Gutenberg University of Mainz
| 4 years |
| Andreas Kretschmer | M | 75 |
The Johannes Gutenberg University of Mainz
| 3 years |
| Wolfgang Seibold | M | - |
Universität Ulm
| 6 years |
| Hans-Helmut Kotz | M | 67 |
The Johannes Gutenberg University of Mainz
| 4 years |
| G. E. Hubertus Krossa | M | 76 |
The Johannes Gutenberg University of Mainz
| 5 years |
| Leopold Eberhart | M | 57 |
Universität Ulm
| 6 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Germany | 35 | 71.43% |
| United States | 14 | 28.57% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Stefan Kaufmann
- Personal Network
